Clinical Trial Update: A Phase 1 Dose Escalation and Expansion Study of AK117 [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation and expansion study of AK117 for malignant neoplasms has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• AK117 (AK117)

Snippet

Sponsor: Akeso | Conditions: Neoplasms Malignant | Phase 1 | Status: COMPLETED